Long-term s afety of pa clitaxel d r ug-coa t ed balloon-only an gioplasty for de novo coronary artery disease: the SPARTAN DCB study

ConclusionWe found no evidence of late mortality associated with DCB angioplasty compared with non-paclitaxel second-generation DES in up to 5 years follow-up. DCB is a safe option for the treatment of de novo coronary artery disease.
Source: Clinical Research in Cardiology - Category: Cardiology Source Type: research